Major improvement in thyroid cancer survival of elderly patients in the Nordic countries

Author:

Zitrický František1,Koskinen Anni23,Liska Vaclav14,Försti Asta56,Hemminki Akseli78ORCID,Hemminki Kari19ORCID

Affiliation:

1. Biomedical Center, Faculty of Medicine, Charles University Pilsen , Pilsen 30605 , Czech Republic

2. Department of Otorhinolaryngology- Head and Neck Surgery, Helsinki University Hospital, University of Helsinki , 00029 Helsinki , Finland

3. Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki , 00029 Helsinki , Finland

4. Biomedical Center, Charles University Medical School , 32300 Pilsen , Czech Republic

5. Hopp Children's Cancer Center (KiTZ) , 69120 Heidelberg , Germany

6. Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK) , 69120 Heidelberg , Germany

7. Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki , 00029 Helsinki , Finland

8. Comprehensive Cancer Center, Helsinki University Hospital , 00029 Helsinki , Finland

9. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ) , Im Neuenheimer Feld 580 , Heidelberg D-69120, Germany

Abstract

Abstract Objectives We describe age-specific survival in thyroid cancer (TC) from Denmark, Finland, Norway, and Sweden over a 50-year period. Design Population-based survival study. Methods Relative 5-year survival data were obtained from the NORDCAN database for the years 1972-2021. Results In the first period 1972-1976, 5-year survival in TC in Finland, Norway, and Sweden was 90% or higher, but a strong negative step-wise age gradient was observed, which was worse for men than women. Over time, survival increased, and in the final period, 2017-2021, survival for all women and Danish men up to age 69 years was about 90% or higher and, for men from the other countries, only marginally lower. Even for older women survival reached 80%, for older men somewhat less. Conclusions Age disadvantage in TC survival was for the most part corrected over the 50-year period, and the remaining task is to boost survival for the oldest patients.

Funder

European Union's Horizon 2020

Jane and Aatos Erkko Foundation

Sigrid Juselius Foundation

Finnish Cancer Organizations

University of Helsinki

Helsinki University Central Hospital

Novo Nordisk Foundation

Päivikki and Sakari Sohlberg Foundation

Cooperatio Program

SURG

National Institute for Cancer Research

European Union—Next Generation EU

Publisher

Oxford University Press (OUP)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3